Status:
COMPLETED
A Study of Econazole Foam 1% in Athlete's Foot
Lead Sponsor:
AmDerma
Conditions:
Tinea Pedis
Athlete's Foot
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a 6-week clinical study (4 weeks of treatment, once per day, plus a 2-week follow-up period) of a topical foam to treat athlete's foot. The active ingredient in the foam -- econazole nitrate 1...
Detailed Description
Treating athlete's foot with a cream can leave a greasy, wet feeling on the foot that is uncomfortable to the user and messy on clothing and foot wear. A foam formulation that spreads easily and rubs-...
Eligibility Criteria
Inclusion
- Be at least 18 years or age and of either sex.
- Has a clinical diagnosis of tinea pedis with at least i) moderate scaling(interdigital and/or moccasin) and ii) mild erythema (interdigital only).
- Be willing to give informed consent.
- Be willing and able to give informed consent.
- Has microscopic evidence (positive KOH) of the presence of fungi. Evaluable subjects must have a positive KOH and a fungal culture positive for a dermatophyte at Baseline. Subjects with a positive KOH may be entered into the study pending the results of the fungal culture.
- Be in good health and free of any disease or physical condition which might, in the investigator's opinion, expose the subject to an unacceptable risk by study participation.
- Women of childbearing potential must have a negative urine pregnancy test and agree to use an effective, non-prohibited form of birth control for the duration of the study (abstinence, stabilized on oral contraceptives for at least two months, implant, injection, IUD, patch, NuvaRing, condom and spermicidal or diaphragm and spermicidal).
Exclusion
- Is nursing or planning a pregnancy during the study.
- Has used topical antifungal or corticosteroid therapy or systemic antibacterial therapy within 30 days prior to the start of the study.
- Has received systemic antifungal therapy within 12 weeks prior to the start of the study medication.
- Has a history of diabetes mellitus or is immunocompromised (due to disease, e.g., HIV, or medications).
- Has concurrent tinea infection (in the opinion of the investigator). However, concurrent onychomycosis is allowed.
- Has any other skin disease which might interfere with the evaluation of tinea pedis.
- Is currently enrolled in an investigational drug or device study.
- Has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study
- Is unreliable, including subjects with a history of drug or alcohol abuse.
- Has known hypersensitivity to any of the components of the study medications.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT00768599
Start Date
March 1 2008
End Date
October 1 2008
Last Update
January 9 2013
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Stacy Smith, MD
San Diego, California, United States, 92123
2
Daniel Stewart, DO
Clinton Township, Michigan, United States, 48038
3
Steven Kempers, MD
Fridley, Minnesota, United States, 55432
4
Michael Gold, MD
Nashville, Tennessee, United States, 37215